Prosight Management
OKUR icon

Prosight Management’s OnKure Therapeutics OKUR Stock Holding History

Prosight Management’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.61M Buy
1,325,570
+346,578
+35% +$1.31M 0.7% 22
2026
Q2 		$4.46M Sell
978,992
-1,175,389
-55% -$5.04M 0.77% 24
2026
Q1 		$8.92M Buy
2,154,381
+1,337,472
+164% +$4.13M 1.46% 21
2025
Q4 		$2.37M Buy
816,909
+548,950
+205% +$1.64M 0.49% 31
2025
Q3 		$737K Buy
267,959
+108,267
+68% +$268K 0.17% 36
2025
Q2 		$382K Sell
159,692
-26,878
-14% -$70.5K 0.09% 37
2025
Q1 		$802K Buy
186,570
+122,816
+193% +$691K 0.26% 34
2024
Q4 		$548K Buy
+63,754
New +$965K 0.15% 36
2021
Q3 		– Sell
-5,493
Closed -$513K – 54
2021
Q2 		$513K Buy
+5,493
New +$613K 0.32% 42

Other funds holding OKUR

Vivo Capital
Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.6B AUM 33.98% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Carlyle Group
Carlyle Group Washington, District of Columbia $8.36B AUM 14.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Prosight Management's OKUR Position: Q3 2026 in Review

Prosight Management increased its OnKure Therapeutics (OKUR) stake by 35% in Q3 2026, buying an estimated $1.31M and bringing the position to 1,325,570 shares worth $3.61M. The position accounts for 0.7% of the portfolio, ranked #22.

Prosight Management first reported a position in OKUR in Q2 2021 and has held it in 9 quarters since. The position peaked at $8.92M in Q1 2026. 45 funds tracked by Wall St. Rank hold OKUR as of Q3 2026.

  • Prosight Management held 1,325,570 shares of OnKure Therapeutics worth $3.61M as of Q3 2026.
  • Prosight Management bought 346,578 OnKure Therapeutics shares in Q3 2026, an estimated $1.31M.
  • OnKure Therapeutics made up 0.7% of Prosight Management's portfolio in Q3 2026, its #22 holding.
  • Prosight Management first reported a position in OnKure Therapeutics in Q2 2021 and has held it in 9 quarters since.
  • Prosight Management's OnKure Therapeutics position peaked at $8.92M in Q1 2026.
  • 45 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q3 2026.

Based on Prosight Management's 13F filing for Q3 2026, filed 13 Nov 2026.